show help

De Clercq E

Author page

This page provides a summary of the entries in Polbase associated with this author.

The publication history graph presents the number of publications in Polbase by this author over time.

The polymerase chart indicates which polymerases this author has published on.

Polbase automatically discovers many polymerase papers as they are published. Some relevant papers are not included because the algorithm is designed to reduce background. Please contribute to polbase by adding your missing DNA polymerase papers.

Help icons:

The show help symbol in the upper-right corner of the page links to this help text. The question mark icon is used everywhere to indicate that help is available.

Missing references?

Publications:

Title Authors Year Journal
N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase. De Clercq E Nucleosides, nucleotides & nucleic acids
Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. De Clercq E Nucleosides, nucleotides & nucleic acids
New developments in anti-HIV chemotherapy. De Clercq E Farmaco (Società chimica italiana : 1989)
Novel compounds in preclinical/early clinical development for the treatment of HIV infections. De Clercq E Reviews in medical virology
Discovery, development and characterization of agents active against the AIDS virus. De Clercq E Journal of receptor and signal transduction research
[Current acquisitions in antiviral drugs (anti-HIV)]. De Clercq E Journal de pharmacie de Belgique
Perspectives for the chemotherapy of AIDS. De Clercq E Anticancer research
Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E Farmaco (Società chimica italiana : 1989)
Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. De Clercq E 2013 ChemMedChem
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. De Clercq E 2013 Bioorganic & medicinal chemistry
Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. De Clercq E 2013 Bioorganic & medicinal chemistry letters
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: Synthesis, biological investigation and molecular modeling studies. De Clercq E 2013 Bioorganic & medicinal chemistry
Design, Synthesis, and Biological Evaluation of Novel 3,5-Disubstituted-1,2,6-Thiadiazine-1,1-Dione Derivatives as HIV-1 NNRTIs. De Clercq E 2013 Chemical biology & drug design
The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS). De Clercq E 2013 Advances in pharmacology (San Diego, Calif.)
Dancing with chemical formulae of antivirals: a personal account. De Clercq E 2013 Biochemical pharmacology
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2013 European journal of medicinal chemistry
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. De Clercq E 2012 European journal of medicinal chemistry
The HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (Part V ☆ ): Capravirine and Its Analogues. De Clercq E 2012 Current medicinal chemistry
Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors. De Clercq E 2012 Current pharmaceutical design
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. De Clercq E 2012 Journal of medicinal chemistry
Dihydro-alkoxyl-benzyl-oxopyrimidine derivatives (DABOs) as non-nucleoside reverse transcriptase inhibitors: an update review (2001-2011). De Clercq E 2012 Current medicinal chemistry
Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. De Clercq E 2012 Current medicinal chemistry
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. De Clercq E 2012 Bioorganic & medicinal chemistry
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. De Clercq E 2012 Bioorganic & medicinal chemistry letters
Arylazolylthioacetanilide. Part 11: Design, Synthesis and Biological Evaluation of 1,2,4-Triazole Thioacetanilide Derivatives as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. De Clercq E 2012 Medicinal chemistry (Shāriqah (United Arab Emirates))
Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2012 European journal of medicinal chemistry
HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. De Clercq E 2011 Medicinal research reviews
Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors. De Clercq E 2011 ChemMedChem
Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. De Clercq E 2011 Current medicinal chemistry
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2011 Bioorganic & medicinal chemistry
Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. De Clercq E 2011 ChemMedChem
A 40-year journey in search of selective antiviral chemotherapy. De Clercq E 2011 Annual review of pharmacology and toxicology
Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2010 Bioorganic & medicinal chemistry
1,2,3-thiadiazole thioacetanilides. Part 2: Synthesis and biological evaluation of a new series of 2-{[4-(3,4-dichlorophenyl)-1,2,3-thiadiazol-5-yl]sulfanyl}acetanilides as HIV-1 inhibitors. De Clercq E 2010 Chemistry & biodiversity
Antiretroviral drugs. De Clercq E 2010 Current opinion in pharmacology
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. De Clercq E 2010 Bioorganic & medicinal chemistry
In search of a selective therapy of viral infections. De Clercq E 2010 Antiviral research
Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. De Clercq E 2010 Antiviral research
Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. De Clercq E 2010 ChemMedChem
Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. De Clercq E 2010 Bioorganic & medicinal chemistry
Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. De Clercq E 2009 ChemMedChem
Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents. De Clercq E 2009 Archiv der Pharmazie
Drug targets in cytomegalovirus infection. De Clercq E 2009 Infectious disorders drug targets
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. De Clercq E 2009 International journal of antimicrobial agents
Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2009 European journal of medicinal chemistry
Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. De Clercq E 2009 Mini reviews in medicinal chemistry
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2009 European journal of medicinal chemistry
1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. De Clercq E 2009 Bioorganic & medicinal chemistry
Design strategies of novel NNRTIs to overcome drug resistance. De Clercq E 2009 Current medicinal chemistry
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. De Clercq E 2009 Expert opinion on pharmacotherapy
Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2009 European journal of medicinal chemistry
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase. De Clercq E 2009 J Med Chem
Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain. De Clercq E 2009 Chemistry & biodiversity
Non-nucleoside reverse transcriptase inhibitors (Part 18): synthesis and anti-HIV activity of 4-allylamino or 4-azido substituted diaryltriazines. De Clercq E 2009 Yao xue xue bao = Acta pharmaceutica Sinica
Inhibition of tubulin polymerization by select alkenyldiarylmethanes. De Clercq E 2008 Bioorganic & medicinal chemistry letters
Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. De Clercq E 2008 Bioorganic & medicinal chemistry
Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. De Clercq E 2008 J Virol
Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2008 Bioorganic & medicinal chemistry
Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues. De Clercq E 2008 Chemistry & biodiversity
Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity. De Clercq E 2008 European journal of medicinal chemistry
Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs). De Clercq E 2008 Bioorganic & medicinal chemistry
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. De Clercq E 2008 Antimicrobial agents and chemotherapy
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors. De Clercq E 2008 Bioorganic & medicinal chemistry letters
Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. De Clercq E 2008 European journal of medicinal chemistry
2-(2,6-Dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1, 3-thiazolidin-4-ones: anti-HIV agents. De Clercq E 2008 Chemical biology & drug design
Emerging antiviral drugs. De Clercq E 2008 Expert opinion on emerging drugs
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. De Clercq E 2008 Bioorganic & medicinal chemistry letters
Recent advances in the research of HIV-1 RNase H inhibitors. De Clercq E 2008 Mini reviews in medicinal chemistry
Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2007 European journal of medicinal chemistry
Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2007 Journal of medicinal chemistry
Antiviral activity of 3-(3,5-dimethylbenzyl)uracil derivatives against HIV-1 and HCMV. De Clercq E 2007 Nucleosides, nucleotides & nucleic acids
Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs. De Clercq E 2007 Molecules (Basel, Switzerland)
Nitroimidazoles Part 6. Synthesis, structure and in vitro anti-HIV activity of new 5-substituted piperazinyl-4-nitroimidazole derivatives. De Clercq E 2007 Antiviral chemistry & chemotherapy
Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4-ones as anti-HIV agents. De Clercq E 2007 Medicinal chemistry (Shāriqah (United Arab Emirates))
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. De Clercq E 2007 Journal of medicinal chemistry
Anti-HIV drugs. De Clercq E 2007 Verhandelingen - Koninklijke Academie voor Geneeskunde van België
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates. De Clercq E 2007 Antimicrobial agents and chemotherapy
Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. De Clercq E 2007 Bioorganic & medicinal chemistry
Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. De Clercq E 2007 Journal of virology
DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. De Clercq E 2007 Antivir Ther
Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. De Clercq E 2007 Antiviral research
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. De Clercq E 2007 Bioorganic & medicinal chemistry letters
Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives. De Clercq E 2007 Acta pharmaceutica (Zagreb, Croatia)
Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents. De Clercq E 2006 Journal of medicinal chemistry
Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses. De Clercq E 2006 Antiviral research
Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. De Clercq E 2006 Bioorganic & medicinal chemistry
Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil derivatives. De Clercq E 2006 Chemical & pharmaceutical bulletin
Nitroimidazoles, part 2: Synthesis, antiviral and antitumor activity of new 4-nitroimidazoles. De Clercq E 2006 Chemistry & biodiversity
Non-nucleoside HIV-1 reverse transcriptase inhibitors, Part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues. De Clercq E 2006 Chemical & pharmaceutical bulletin
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. De Clercq E 2006 Journal of virology
Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents. De Clercq E 2005 Journal of the American Chemical Society
Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors. De Clercq E 2005 Journal of medicinal chemistry
Antiviral drug discovery and development: where chemistry meets with biomedicine. De Clercq E 2005 Antiviral research
Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. De Clercq E 2005 Journal of virology
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU). De Clercq E 2005 Medicinal research reviews
Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. De Clercq E 2005 Molecular pharmacology
Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action. De Clercq E 2005 The Journal of antimicrobial chemotherapy
The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A. De Clercq E 2005 Molecular pharmacology
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. De Clercq E 2005 FEBS letters
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. De Clercq E 2005 Molecular pharmacology
Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. De Clercq E 2005 Antimicrobial agents and chemotherapy
Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. De Clercq E 2005 Antimicrobial agents and chemotherapy
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication. De Clercq E 2005 Journal of medicinal chemistry
Nonnucleoside HIV-1 reverse-transcriptase inhibitors, part 5. Synthesis and anti-HIV-1 activity of novel 6-naphthylthio HEPT analogues. De Clercq E 2005 Chemical & pharmaceutical bulletin
Non-nucleoside HIV reverse transcriptase inhibitors, Part 6[1]: synthesis and anti-HIV activity of novel 2-[(arylcarbonylmethyl)thio]-6-arylthio DABO analogues. De Clercq E 2005 Archiv der Pharmazie
Emerging anti-HIV drugs. De Clercq E 2005 Expert Opin Emerg Drugs
5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. De Clercq E 2004 Bioorganic & medicinal chemistry letters
Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. De Clercq E 2004 Bioorganic chemistry
2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2004 Antiviral research
Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. De Clercq E 2004 Farmaco (Società chimica italiana : 1989)
Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. De Clercq E 2004 Molecular pharmacology
Antiviral drugs in current clinical use. De Clercq E 2004 J Clin Virol
Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. De Clercq E 2004 Antiviral Res
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors. De Clercq E 2004 Journal of medicinal chemistry
In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? De Clercq E 2004 Antiviral research
Novel inhibitors of HIV-1 integration. De Clercq E 2004 Current drug metabolism
Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. De Clercq E 2004 Biochemical pharmacology
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. De Clercq E 2004 AIDS (London, England)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. De Clercq E 2004 Chemistry & biodiversity
The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. De Clercq E 2004 Journal of virology
Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors. De Clercq E 2003 Antiviral chemistry & chemotherapy
Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. De Clercq E 2003 Antiviral chemistry & chemotherapy
Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. De Clercq E 2003 AIDS research and human retroviruses
Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. De Clercq E 2003 Antimicrobial agents and chemotherapy
Anti-HIV agents: design and discovery of new potent RT inhibitors. De Clercq E 2003 Farmaco (Società chimica italiana : 1989)
Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. De Clercq E 2003 Antiviral research
Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. De Clercq E 2003 Antimicrobial agents and chemotherapy
Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. De Clercq E 2003 Antimicrobial agents and chemotherapy
Nonnucleoside HIV-1 reverse transcriptase inhibitors: Part I. Synthesis and structure-activity relationship of 1-alkoxymethyl-5-alkyl-6-naphthylmethyl uracils as HEPT analogues. De Clercq E 2003 Chemical & pharmaceutical bulletin
Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMV. De Clercq E 2003 Antiviral chemistry & chemotherapy
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action. De Clercq E 2003 Journal of medicinal chemistry
Synthesis and antiviral activity of some 5'-N-phthaloyl-3'-azido-2',3'-dideoxythymidine analogues. De Clercq E 2003 Antiviral chemistry & chemotherapy
Synthesis, solution conformation and anti-HIV activity of novel 3'-substituted-2',3'-dideoxy-5-hydroxymethyluridines and their 4,5-substituted analogues. De Clercq E 2003 Antiviral chemistry & chemotherapy
Characterization of the catalytic subunit of the human herpesvirus 6 (HHV-6) DNA polymerase expressed in an in vitro transcription/translation assay. De Clercq E 2003 Nucleosides, nucleotides & nucleic acids
Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus. De Clercq E 2002 Journal of medical virology
Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999. De Clercq E 2002 Virus research
New developments in anti-HIV chemotherapy. De Clercq E 2002 Biochimica et biophysica acta
New class of HIV integrase inhibitors that block viral replication in cell culture. De Clercq E 2002 Current biology : CB
Highlights in the development of new antiviral agents. De Clercq E 2002 Mini reviews in medicinal chemistry
New anti-HIV agents and targets. De Clercq E 2002 Medicinal research reviews
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. De Clercq E 2002 Antimicrobial agents and chemotherapy
2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. De Clercq E 2002 Antiviral research
In search of authentic inhibitors of HIV-1 integration. De Clercq E 2002 Antiviral chemistry & chemotherapy
Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors. De Clercq E 2002 Molecular pharmacology
Synthesis of 3' '-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. De Clercq E 2002 Journal of medicinal chemistry
Evaluating phenotype and genotype of drug-resistant strains in herpesviruses. De Clercq E 2001 Molecular biotechnology
Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. De Clercq E 2001 Antiviral therapy
The anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. De Clercq E 2001 Antiviral research
New developments in anti-HIV chemotherapy. De Clercq E 2001 Current medicinal chemistry
Anti-HIV-1 activity of benzothiadiazine dioxide. De Clercq E 2001 Antiviral chemistry & chemotherapy
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). De Clercq E 2001 Bioorganic & medicinal chemistry letters
Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture. De Clercq E 2001 AIDS research and human retroviruses
Identification of a novel family of nucleosides that specifically inhibit HIV-1 reverse transcriptase. De Clercq E 2001 Bioorganic & medicinal chemistry letters
Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: non-nucleoside HIV-1 reverse transcriptase inhibitors. De Clercq E 2001 Antiviral chemistry & chemotherapy
HIV-1 integration as a target for antiretroviral therapy: a review. De Clercq E 2001 Current drug targets. Infectious disorders
Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT. De Clercq E 2001 Virology
Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. De Clercq E 2001 Journal of virology
Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. De Clercq E 2001 Virology
Hamao Umezawa Memorial Award Lecture: "An Odyssey in the Viral Chemotherapy Field". De Clercq E 2001 International journal of antimicrobial agents
Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. De Clercq E 2001 Antiviral chemistry & chemotherapy
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. De Clercq E 2000 Antimicrobial agents and chemotherapy
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients. De Clercq E 2000 AIDS research and human retroviruses
Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes. De Clercq E 2000 The Biochemical journal
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. De Clercq E 2000 Molecular pharmacology
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. De Clercq E 2000 AIDS research and human retroviruses
Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs. De Clercq E 2000 Methods in molecular medicine
Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. De Clercq E 2000 Antiviral research
Novel agents for the therapy of varicella-zoster virus infections. De Clercq E 2000 Expert opinion on investigational drugs
Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. De Clercq E 2000 Molecular pharmacology
Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain. De Clercq E 2000 Bioorganic & medicinal chemistry
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. De Clercq E 2000 Medicinal research reviews
In vitro evaluation of the effect of temporary removal of HIV drug pressure. De Clercq E 2000 Antiviral research
Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184. De Clercq E 2000 European journal of biochemistry / FEBS
Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. De Clercq E 2000 Journal of viral hepatitis
The HIV-1 reverse transcription (RT) process as target for RT inhibitors. De Clercq E 2000 Medicinal research reviews
Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. De Clercq E 2000 The Journal of general virology
9-(2-Phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase. De Clercq E 1999 Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research
The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses. De Clercq E 1999 Transplantation
Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. De Clercq E 1999 Drugs
Inhibition of human immunodeficiency virus type (HIV-1) replication by some diversely functionalized spirocyclopropyl derivatives. De Clercq E 1999 Archiv der Pharmazie
Perspectives for the treatment of hepatitis B virus infections. De Clercq E 1999 International journal of antimicrobial agents
Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. De Clercq E 1999 AIDS (London, England)
Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. De Clercq E 1999 Antimicrobial agents and chemotherapy
Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors. De Clercq E 1999 Bioorganic & medicinal chemistry
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. De Clercq E 1999 Biochemical pharmacology
Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region. De Clercq E 1999 Journal of medicinal chemistry
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. De Clercq E 1998 Journal of virological methods
Treatment of visna virus infection in lambs with the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)adenine (PMEA). De Clercq E 1998 Antiviral chemistry & chemotherapy
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E 1998 Antiviral research
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. De Clercq E 1998 AIDS (London, England)
The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. De Clercq E 1998 Antimicrobial agents and chemotherapy
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. De Clercq E 1998 Antimicrobial agents and chemotherapy
A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. De Clercq E 1998 The Journal of general virology
Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. De Clercq E 1998 AIDS research and human retroviruses
The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. De Clercq E 1998 Antimicrobial agents and chemotherapy
New perspectives for the treatment of HIV infections. De Clercq E 1998 Verhandelingen - Koninklijke Academie voor Geneeskunde van België
Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. De Clercq E 1998 Journal of medicinal chemistry
Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. De Clercq E 1998 Journal of medicinal chemistry
An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase. De Clercq E 1998 Antiviral chemistry & chemotherapy
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. De Clercq E 1997 Journal of virology
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. De Clercq E 1997 Antimicrobial agents and chemotherapy
SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. De Clercq E 1997 Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. De Clercq E 1997 Biochemical and biophysical research communications
Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine. De Clercq E 1997 The Journal of infectious diseases
Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem? De Clercq E 1997 International journal of antimicrobial agents
In search of a selective antiviral chemotherapy. De Clercq E 1997 Clinical microbiology reviews
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. De Clercq E 1997 General pharmacology
Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. De Clercq E 1997 Gene therapy
Reverse transcriptase fidelity and HIV-1 variation. De Clercq E 1997 Science (New York, N.Y.)
Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. De Clercq E 1996 Biochemical and biophysical research communications
Analysis of inhibition of retroviral reverse transcriptase. De Clercq E 1996 Methods in enzymology
A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1. De Clercq E 1996 Journal of virological methods
Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity. De Clercq E 1996 Antiviral research
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine. De Clercq E 1996 Molecular pharmacology
Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. De Clercq E 1996 Antimicrobial agents and chemotherapy
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. De Clercq E 1996 Molecular pharmacology
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. De Clercq E 1996 AIDS (London, England)
New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. De Clercq E 1996 Antiviral research
Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. De Clercq E 1996 Antiviral research
Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. De Clercq E 1996 Journal of medicinal chemistry
Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. De Clercq E 1996 Journal of medicinal chemistry
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. De Clercq E 1996 Medicinal research reviews
Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. De Clercq E 1996 Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
Chemical crosslinking of the subunits of HIV-1 reverse transcriptase. De Clercq E 1996 Protein science : a publication of the Protein Society
Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle. De Clercq E 1996 Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. De Clercq E 1996 Verhandelingen - Koninklijke Academie voor Geneeskunde van België
Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. De Clercq E 1995 Biochemical and biophysical research communications
Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains. De Clercq E 1995 Antimicrobial agents and chemotherapy
Antiviral therapy for human immunodeficiency virus infections. De Clercq E 1995 Clinical microbiology reviews
Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. De Clercq E 1995 Antiviral research
Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. De Clercq E 1995 Journal of medicinal chemistry
Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? De Clercq E 1995 Farmaco (Società chimica italiana : 1989)
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). De Clercq E 1995 Proceedings of the National Academy of Sciences of the United States of America
Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit. De Clercq E 1994 The Journal of biological chemistry
Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. De Clercq E 1994 Biochemical and biophysical research communications
Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. De Clercq E 1994 Molecular pharmacology
Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. De Clercq E 1994 Biochemical pharmacology
HIV resistance to reverse transcriptase inhibitors. De Clercq E 1994 Biochemical pharmacology
Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. De Clercq E 1994 Antimicrobial agents and chemotherapy
New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors. De Clercq E 1994 Annals of the New York Academy of Sciences
How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors. De Clercq E 1994 AIDS (London, England)
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs. De Clercq E 1994 Antimicrobial agents and chemotherapy
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. De Clercq E 1994 Journal of virology
Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants. De Clercq E 1994 Proceedings of the National Academy of Sciences of the United States of America
Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. De Clercq E 1993 Virology
Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs. De Clercq E 1993 Antimicrobial agents and chemotherapy
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues. De Clercq E 1993 Molecular pharmacology
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. De Clercq E 1993 Virology
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. De Clercq E 1993 Journal of virology
Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo. De Clercq E 1993 European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors. De Clercq E 1993 Molecular pharmacology
HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. De Clercq E 1993 Medicinal research reviews
Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. De Clercq E 1993 Molecular pharmacology
Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. De Clercq E 1993 Advances in virus research
[Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase]. De Clercq E 1993 Pathologie-biologie
Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. De Clercq E 1992 Virology
Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. De Clercq E 1992 Molecular pharmacology
3'-C-branched 2'-deoxy-5-methyluridines: synthesis, enzyme inhibition, and antiviral properties. De Clercq E 1992 Journal of medicinal chemistry
Anti-human immunodeficiency virus effects of cationic metalloporphyrin-ellipticine complexes. De Clercq E 1992 Biochemical pharmacology
Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T). De Clercq E 1992 The Journal of biological chemistry
[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. De Clercq E 1992 Antimicrobial agents and chemotherapy
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. De Clercq E 1992 Proceedings of the National Academy of Sciences of the United States of America
Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus. De Clercq E 1992 The Journal of general virology
Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. De Clercq E 1992 The Journal of biological chemistry
Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase. De Clercq E 1992 Molecular pharmacology
HIV inhibitors targeted at the reverse transcriptase. De Clercq E 1992 AIDS research and human retroviruses
New perspectives for the chemotherapy and chemoprophylaxis of AIDS (acquired immune deficiency syndrome). De Clercq E 1992 Verhandelingen - Koninklijke Academie voor Geneeskunde van België
Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds. De Clercq E 1992 Molecular pharmacology
Specific HIV-1 reverse transcriptase inhibitors. De Clercq E 1992 Journal of enzyme inhibition
Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. De Clercq E 1991 Proceedings of the National Academy of Sciences of the United States of America
Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. De Clercq E 1991 Molecular pharmacology
Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. De Clercq E 1991 Proceedings of the National Academy of Sciences of the United States of America
Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues. De Clercq E 1991 International journal of immunopharmacology
Chemotherapy of the acquired immune deficiency syndrome (AIDS): non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase. De Clercq E 1991 International journal of immunopharmacology
Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. De Clercq E 1991 Journal of medicinal chemistry
Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. De Clercq E 1991 Journal of medicinal chemistry
Inhibition of the growth of Plasmodium falciparum and Plasmodium berghei by the DNA polymerase inhibitor HPMPA. De Clercq E 1991 Mol Biochem Parasitol
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. De Clercq E 1991 Proceedings of the National Academy of Sciences of the United States of America
5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. De Clercq E 1991 The Journal of biological chemistry
9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. De Clercq E 1991 Proceedings of the National Academy of Sciences of the United States of America
Differential inhibition of retroviral reverse transcriptase by poly(2-fluoroadenylic acid), a template analogue. De Clercq E 1991 AIDS (London, England)
Selective virus inhibitors. De Clercq E 1990 Microbiologica
Targets and strategies for the antiviral chemotherapy of AIDS. De Clercq E 1990 Trends in pharmacological sciences
Mechanism of action of 5-(2-chloroethyl)-2'-deoxyuridine, a selective inhibitor of herpes simplex virus replication. De Clercq E 1990 Molecular pharmacology
Potent inhibitory effects of the 5'-triphosphates of (E)-5-(2-bromovinyl)-2'-deoxyuridine and (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on DNA polymerase gamma. De Clercq E 1990 Eur J Biochem
Treatment of bovine leukaemia virus-infected sheep with suramin: an animal model for the development of antiretroviral compounds. De Clercq E 1989 Acta virologica
Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. De Clercq E 1989 Biochemical and biophysical research communications
Potential drugs for the treatment of AIDS. De Clercq E 1989 The Journal of antimicrobial chemotherapy
Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro. De Clercq E 1989 Journal of acquired immune deficiency syndromes
Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells. De Clercq E 1989 Journal of acquired immune deficiency syndromes
Differential inhibitory effects of several pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. De Clercq E 1989 Molecular pharmacology
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. De Clercq E 1989 Biochemical and biophysical research communications
Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein. De Clercq E 1989 Nucleic acids research
Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid. De Clercq E 1988 European journal of biochemistry / FEBS
Perspectives for the chemotherapy of AIDS. De Clercq E 1988 Chemioterapia : international journal of the Mediterranean Society of Chemotherapy
Inhibitory activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the salmonid herpesviruses, Oncorhynchus masou virus (OMV) and Herpesvirus salmonis. De Clercq E 1988 Microbiology and immunology
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. De Clercq E 1988 Proceedings of the National Academy of Sciences of the United States of America
Fuchsin acid selectively inhibits human immunodeficiency virus (HIV) replication in vitro. De Clercq E 1988 Biochemical and biophysical research communications
Alpha, beta- and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine-5'-triphosphate. Correlation between affinity for reverse transcriptase, susceptibility to hydrolysis by phosphodiesterases and anti-retrovirus activity. De Clercq E 1988 Biochemical pharmacology
Incorporation of the carbocyclic analogue of (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate into a synthetic DNA. De Clercq E 1987 Biochemical and biophysical research communications
Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. De Clercq E 1987 Antiviral research
Suramin in the treatment of AIDS: mechanism of action. De Clercq E 1987 Antiviral research
Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinase. De Clercq E 1987 Antiviral research
Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). De Clercq E 1986 International journal of cancer. Journal international du cancer
Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. De Clercq E 1986 Biochemical and biophysical research communications
Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins. De Clercq E 1986 Biochemical and biophysical research communications
Inhibitors of reverse transcriptase and retrovirus replication. De Clercq E 1985 Arzneimittel-Forschung
Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate. De Clercq E 1984 Molecular pharmacology
Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. De Clercq E 1984 Pharmacology & therapeutics
Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. De Clercq E 1984 Antiviral Res
Inhibition of terminal deoxynucleotidyltransferase by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate. De Clercq E 1983 Nucleic acids symposium series
Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine. De Clercq E 1983 The Biochemical journal
Baculovirus replication: inhibition of Trichoplusia ni multiple nuclear polyhedrosis virus by [E]-5-(2-bromovinyl)-2'-deoxyuridine. De Clercq E 1983 The Journal of general virology
Inhibition of murine leukaemia virus reverse transcriptase by 2-halogenated polyadenylic acids. De Clercq E 1982 The Biochemical journal
Inhibitory effect of E-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on herpes simplex virus replication and DNA synthesis. De Clercq E 1982 Journal of virology
On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. De Clercq E 1981 Proceedings of the National Academy of Sciences of the United States of America
Influence of various 2- and 2'-substituted polyadenylic acids on murine leukemia virus reverse transcriptase. De Clercq E 1979 Cancer letters
Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. De Clercq E 1979 Cancer letters
Gliotoxin analogues as inhibitors of reverse transcriptase. 2. Resolution and X-ray crystal structure determination. De Clercq E 1978 Journal of medicinal chemistry
Gliotoxin analogues as inhibitors of reverse transcriptase. 1. Effect of lipophilicity. De Clercq E 1978 Journal of medicinal chemistry
Interferon induction by polynucleotides: structure-function relationship. De Clercq E 1977 Texas reports on biology and medicine
Biologic activities of poly (2-azaadenylic acid) and poly (2-azainosinic acid). De Clercq E 1977 Nucleic acids research
Role of purine N-3 in the biologic activities of poly(A) and poly(I). De Clercq E 1976 Nucleic acids research
Inhibition of oncornavirus functions by 2'-azido polynucleotides. De Clercq E 1975 Proceedings of the National Academy of Sciences of the United States of America
Inhibition of oncornavirus functions by poly (2-methylthioinosinic acid). De Clercq E 1975 Nucleic acids research
Proceedings: Inhibition of mouse leukemia virus RNA-dependent DNA polymerase by 2'-OH-substituted polynucleotides. De Clercq E 1974 Hoppe-Seyler's Zeitschrift für physiologische Chemie
A more sensitive assay system for the detection of RNA-dependent DNA polymerase in oncogenic RNA viruses. De Clercq E 1973 Biochimica et biophysica acta
All Authors

Using Polbase tables:

Sorting:

Tables may be sorted by clicking on any of the column titles. A second click reverses the sort order. <Ctrl> + click on the column titles to sort by more than one column (e.g. family then name).

Filtering:

It is also possible to filter the table by typing into the search box above the table. This will instantly hide lines from the table that do not contain your search text.